Payment overview · 2025
General Payments
$45,231.42
173 reported records · 31 companies
Healthcare provider profile · identity verified
Khaled Imad Khalaf, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · HUMBLE, TX · NPI 1710237250
Verified facts
What the public records show
CMS Open Payments records show Khaled Imad Khalaf, M.D. received $45,231.42 in general payments during 2025 across 173 reported records.
CARDIVA MEDICAL, INC. accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $16,167.20 | 35.7% | 6 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $12,966.44 | 28.7% | 16 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$6,870.14 | 15.2% | 35 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $5,236.44 | 11.6% | 30 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,296.07 | 2.9% | 17 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $375.97 | 0.8% | 6 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $369.05 | 0.8% | 14 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $330.99 | 0.7% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $204.74 | 0.5% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $199.56 | 0.4% | 4 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $199.20 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $187.49 | 0.4% | 11 | 2025 |
| ENDOTRONIX, INC. | Unresolved — no canonical attribution shown | $146.57 | 0.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $124.14 | 0.3% | 5 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $108.91 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.56 | 0.1% | 3 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $60.05 | 0.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.03 | 0.1% | 2 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $38.03 | 0.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $32.15 | 0.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $28.30 | 0.1% | 1 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.06 | 0.1% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $25.69 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.15 | 0.1% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $22.10 | 0.1% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $21.48 | 0.1% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $16.20 | 0.0% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $16.08 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.96 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.86 | 0.0% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $4.81 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $20,500.00 | 4 |
| Travel and Lodging | $7,812.72 | 11 |
| Food and Beverage | $6,478.70 | 155 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,440.00 | 2 |
| Long term medical supply or device loan | $5,000.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SAVVYWIRE Normalized: savvywire |
Device | CARDIVA MEDICAL, INC. | $16,167.20 | 6 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $12,966.44 | 16 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $5,715.92 | 9 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $5,236.44 | 30 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $1,080.15 | 23 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $694.63 | 11 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $375.97 | 6 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $369.05 | 14 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $330.99 | 3 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $330.99 | 3 | 2025 |
Source payment records
|
|||||
| ADVISOR Normalized: advisor |
Device | Abbott Laboratories | $235.98 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $204.74 | 3 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $199.20 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $187.49 | 11 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $148.52 | 1 | 2025 |
Source payment records
|
|||||
| CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Normalized: cordella pulomonary artery pressure sensor |
Device | ENDOTRONIX, INC. | $146.57 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $128.64 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $128.62 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $124.14 | 5 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $108.91 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $67.04 | 2 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $65.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $61.56 | 3 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $60.05 | 2 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $38.03 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $35.82 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $35.12 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $32.15 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $28.30 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Pharmaceuticals, Inc. | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| LifeStream Normalized: lifestream |
Device | Bard Peripheral Vascular, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $7.03 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $4.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
85 | 29 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
82 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 371 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 205 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 72 |
| Furosemide | Furosemide | 172 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 119 | 42 |
| Xarelto | Rivaroxaban | 113 | 41 |
| Carvedilol | Carvedilol | 110 | 42 |
| Losartan Potassium | Losartan Potassium | 103 | 47 |
| Eliquis | Apixaban | 85 | 29 |
| Entresto | Sacubitril/Valsartan | 82 | 28 |
| Lisinopril | Lisinopril | 72 | 29 |
| Ezetimibe | Ezetimibe | 67 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 19 |
| Brilinta | Ticagrelor | 51 | 19 |
| Potassium Chloride | Potassium Chloride | 47 | 20 |
| Fenofibrate | Fenofibrate | 43 | 16 |
| Farxiga | Dapagliflozin Propanediol | 40 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 12 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | 13 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Valsartan | Valsartan | 24 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Prednisone | Prednisone | 20 | 14 |
| Simvastatin | Simvastatin | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Repatha Pushtronex | Evolocumab | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45,231.42 · 173 records | CARDIVA MEDICAL, INC. | ADVISOR, AFFERA MAPPING SYSTEM, AURYON LASER SYSTEM 100-120 VAC, AVVIGO Guidance System, Asahi Peripheral Vascular Wires, Assure WCD, Barostim Neo System, BioMimics 3D Vascular Stent System, CAMZYOS, CAPVAXIVE, CARDIOMEMS, CLOT MANAGEMENT, CORDELLA PULOMONARY ARTERY PRESSURE SENSOR, COREVALVE EVOLUT R, ENDOCROSS Device, EVKEEZA, FFRct, GORE CARDIOFORM Septal Occluder, JARDIANCE, KENGREAL, Kerendia, LEQVIO, LYMPHA PRESS OPTIMAL PLUS(US) BT, LifeStream, LifeVest, MERLIN@HOME, NAVITOR, OPSUMIT, Ozempic, PCD-51 731A (US) - White, PCD-52 737A (US) White, Paradise Ultrasound Renal Denervation System, Rybelsus, SAPIEN 3 Ultra RESILIA, SAVVYWIRE, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRICLIP, Torus Stent Graft System, UPTRAVI, VENASEAL, VERQUVO, Varithena Administration Pack, WATCHMAN FLX, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error